Search: 
You do not have permission to access this chart.
Please Sign Up or Login
News for BioVie Inc. (BIVI)
Newly released Crypto mining rig for BioVie Inc. coins
minutes ago | Banggood.com
Everything Crypto on sale now!
58 minutes ago | Aliexpress.com
BioVie Inc. Announces Closing of Public Offering of Common Stock
4 days ago | GlobeNewsWire
BioVie Stock Plunges On $20M Capital Raise Via Equity At Deep Discount Of 38%
6 days ago | Benzinga
BioVie Inc. Announces Pricing of Public Offering of Common Stock
6 days ago | GlobeNewsWire
BioVie Inc. Announces Proposed Public Offering of Common Stock
a week ago | GlobeNewsWire
Basis for BioVie's Phase 3 Clinical Trial of NE3107 in the Treatment of Alzheimer's Disease Published in Neurodegenerative Disease Management
a month ago | GlobeNewsWire
Development of BioVie's NE3107 Asset Featured by the American Diabetes Association
a month ago | GlobeNewsWire
BioVie Added to Russell Microcap® Index
a month ago | GlobeNewsWire
BioVie Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®
a month ago | GlobeNewsWire
BioVie Hosting Research & Development Day
3 months ago | GlobeNewsWire
Moving Average Crossover Alert: BioVie (BIVI)
3 months ago | Zacks Investment Research

BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. It develops BIV201, which completed Phase 2a clinical trial for the treatment of ascites due to chronic liver cirrhosis. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was founded in 2013 and is based in Santa Monica, California.

Sector:

Healthcare

Industry:

Biotechnology

Employees:

2

Address:

BioVie Inc. 2120 Colorado Avenue Suite 230 Santa Monica CA 90404 United States

Website:

http://www.biovieinc.com

Phone:

312-283-5793

Leave a comment

Your email address will not be published. Required fields are marked *